Can-Fite BioPharma Company
"Targeted Drugs for Cancer and Inflammatory Diseases."
Can-Fite BioPharma is an advanced clinical-stage drug development company with a platform technology that addresses multi-billion dollar markets in the treatment of autoimmune inflammatory diseases including rheumatoid arthritis and psoriasis, and liver diseases including advanced liver cancer and NASH.
Can-Fite’s drugs have an excellent safety profile and have been used to treat more than 1,000 patients. Namodenoson is currently being used to treat liver cancer patients in Israel under a compassionate use program. The company’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date.
Can-Fite recently entered into a strategic partnership with Univo Pharmaceuticals to develop cannabinoid-based pharmaceuticals and assays.
Combating Coronavirus Pandemic:
Can-Fite BioPharma's solution helps address the Coronavirus Pandemic.
Can-Fite BioPharma is an advanced clinical-stage drug development company with a platform technology that addresses multi-billion dollar markets in the treatment of autoimmune inflammatory diseases including rheumatoid arthritis and psoriasis, and liver diseases including advanced liver cancer and NASH.
Can-Fite’s drugs have an excellent safety profile and have been used to treat more than 1,000 patients. Namodenoson is currently being used to treat liver cancer patients in Israel under a compassionate use program. The company’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date.
Can-Fite recently entered into a strategic partnership with Univo Pharmaceuticals to develop cannabinoid-based pharmaceuticals and assays.
Combating Coronavirus Pandemic:
Can-Fite BioPharma's solution helps address the Coronavirus Pandemic.
Technology:
COVID Treatments
Industry:
Vaccine Development
Headquarters:
Israel
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership